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ABSTRACT
Objective: The aim of this study was to investigate whether insulin deficiency and increased
catabolism may have a role in the regulation of plasma glucagon-like peptide (GLP)-1 and GLP-
2 levels in children with diabetic ketoacidosis (DKA) and whether insulin treatment may affect
the levels of these polypeptides.
Methods: Plasma GLP-1 and -2 levels were measured in 24 patients with DKA aged 8 to 14
years before insulin infusion (time 0), when ketonemia and acidosis disappeared (time 1), and
when weight gain started (time 2). Eighteen healthy children aged 8 to 14 years constituted the
control group. 
Results: At time 0, mean plasma GLP-1 and GLP-2 levels were significantly elevated in the patients
compared with the control group (p<0.05 and p<0.01, respectively). At time 1 when ketonemia and
acidosis disappeared, GLP-1 and GLP-2 levels decreased significantly from the initial levels (p<0.05
and p<0.01, respectively). At this time, while GLP-1 level was not different from that of the controls,
GLP-2 level was higher than that of the controls (p<0.05). GLP-1 and-2 levels did not show any sig-
nificant differences between the patients and controls when weight gain started (time 2). 
Conclusion: Our results show that DKA is associated with increased plasma GLP-1 and -2 con-
centrations. Effective fluid and insulin treatment resulted in a significant decrease in plasma GLP-
1 and -2 levels. This may be due to the negative feedback effect of insulin on the production of
these polypeptides. 
Conflict of interest: None declared
INTRODUCTION 
Glucagon-like peptide-1 (GLP-I) and
GLP-2 are proglucagon-derived peptides
produced in the L-cells of the small intes-
tine and secreted into the circulation after
food intake. GLP-1 stimulates insulin
secretion in a glucose-dependent manner,
and inhibits glucagon secretion, gastric
motility and food intake.(1, 2, 3, 4, 5, 6, 7)
Recent studies also reported that GLP-1
increases pancreatic b-cell mass by stimu-
lating b-cell proliferation and inhibiting b-
cell apoptosis.(8) GLP-1 administration to
rodents and humans lowers plasma fasting
and food-stimulated glycemia, and it has
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also been shown that GLP-1 induces satiety
and reduces food intake in both healthy and
diabetic subjects. GLP-2 does not seem to
regulate blood glucose, but it has
insulinotropic effects on the intestinal
mucosa.(9, 10)It has been shown that GLP-
2 stimulates the proliferation of small intes-
tine and large bowel mucosal epithelial
cells, and inhibits apoptosis both in animals
and humans.(11) GLP-2 also enhances intes-
tinal barrier functions and stimulates intes-
tinal hexose transport.(12, 14)The secretion
of GLP-1, GLP-2 and the other proglucagon
derived peptides into the circulation is stim-
ulated by ingestion of carbohydrate, protein
and fat. Carbohydrate ingestion is the best
stimulus for GLP-1 secretion, in both ani-
mals and humans. Several neural and
humoral factors, are responsible for the
rapid increase in GLP-1 secretion.(15, 16,
17) Although insulin administration to dia-
betic rats decreases the circulating intestinal
proglucagon derived peptides,(18) the
potential inhibitory effect of insulin on the
synthesis of GLP-1 and GLP-2 has not yet
been demonstrated in humans. It has been
reported that type 1 diabetes mellitus
(T1DM) is associated with a decreased GLP-
1 level, whereas less is known about GLP-2
levels.
The aim of the study was to evaluate the
changes of the plasma GLP-1 and GLP-2 lev-
els before and during insulin treatment in
diabetic ketoacidosis (DKA) which is a state
characterized by extreme insulin deficiency.
The study also aimed to investigate the con-
founding parameters in the secretion of
these peptides.
METHODS 
The study included 24 patients (12 boys
and 12 girls) with T1DM, aged 10.5±0.8
(mean±SD) years. The control group con-
sisted of 18 healthy children (10 boys and 8
girls), aged 10.2±1.5 years. Patients were
admitted to our hospital with a diagnosis of
DKA (an arterial pH <7.3, glucose levels
>300 mg/dL, and ketonemia). Only two
subjects had new-onset T1DM. The mean
duration of the diabetes was 25.8±4.5
months. Patients were treated with intra-
venous fluids and continuous insulin infu-
sion according to the DKA treatment proto-
col. Sodium bicarbonate was administered
to patients with an arterial pH<7.2. The total
insulin dose used ranged from 0.52 to 1.41
U/kg over the first 24 hours. All patients
were started on oral fluids and food approx-
imately 9-12 hours after the start of the treat-
ment. Blood was collected for the measure-
ment of plasma GLP-1 and -2 three times:
before starting insulin and fluid treatment
(time 0), when ketonemia resolved (time 1)
and when weight gain started (time 2),
approximately 96 hours after the start of
treatment. Blood was collected from the
control group only once. Heights and
weights were measured by standard meth-
ods and BMI (kg/m2) calculated and
expressed as SDS according to national
standards. 
Detailed consent forms of the study were
signed by the families of the patients and
control group. Local committee approval
was obtained for the study. 
Biochemical analyses: Plasma glucose
concentrations were measured using the glu-
cose oxidase method. Plasma ketone bodies
and glycated hemoglobin (HbA1c) levels
were measured with enzymatic methods
from venous blood samples. Arterial blood
gases were measured with an automatic
blood gas analyzer (Nova Biomedical
pHOXplus L). For the measurement of plas-
ma GLP-1, and GLP-2, blood samples were
collected using a chilled syringe and trans-
fered into a polypropylene tube containing
EDTA (1 mg/ml of blood) and Aprotinin
(500KIU/ml of blood) at 0°C. The blood
sample was centrifuged at 1600 xg for 15
minutes at 0°, and transferred into a fresh
polypropylene tube, and stored at –70°C.
After an extraction procedure for plasma,
GLP-1 levels were measured by ELISA with
the reagents of Peninsula Laboratories, Inc.Glucagon-like Peptide-1 and-2 Levels in Children with Diabetic Ketoacidosis
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(San Carlos, California) with the detection
range of 0-25 ng/ml for standard curve and
GLP-2 levels were measured by RIA with the
reagents of Peninsula Laboratories, Inc. (San
Carlos, California) with the detection range
of 10-1280 pg/100 µl for standard curve
according to protocols that the producer
company proposed.
Statistical analyses: These were per-
formed using a statistical package (SPSS for
Windows, version 11.01). Study and control
group comparisons were made by the Mann-
Whitney U-test. Intragroup comparisons were
performed by using the Wilcoxon test.
Spearman correlation analysis was used to
investigate the degree of correlation between
age, body weight, BMI, insulin dose, insulin
injection number per day, arterial blood pH,
glycemic control as reflected by HbA1c value
and plasma GLP-1 and GLP-2 concentrations.
The data are expressed as means±SDs in the
text. For all comparisons, statistical signifi-
cance was defined as p< 0.05.
RESULTS
GLP-1 and -2 levels of the study popula-
tion are presented in Table 1. The insulin
and fluid administration effectively
decreased blood glucose levels and
improved the metabolic disturbances. BMI
and BMI SDS values in patients were signif-
icantly lower than those of the control sub-
jects at admission (p<0.05, Table 1). HbA1c
(%) levels were significantly higher in
patients (13.2 ± 4.1) compared with those of
controls (4.1±0.3) (p<0.001). Mean arterial
blood pH value was 7.14±0.04 in the
patients. Plasma ketone bodies disappeared
during the initial 6-8 hours, and arterial
blood pH normalized within 2-4 hours of
treatment. Before treatment, plasma GLP-1
and GLP-2 levels were significantly higher in
patients than in controls (p<0.05 and p<0.01,
respectively, Table 1, Figures 1 and 2).
Plasma GLP-1 levels decreased significantly
at 8th hour after starting treatment (time 1)
when ketonemia resolved (p<0.05, Table 1).
No significant difference was found between
the patients and controls at this time (time 1)
(Table 1, Figure 1). GLP-2 levels also
showed a significant decline from time 0 to
time 1 in the patient group (p<0.05). The
level was significantly higher than in the
controls (p<0.01, Table 1, Figure 2). Plasma
GLP-1 and -2 levels further decreased at time
Table 1: Plasma GLP-1 and -2 levels and BMI, BMI SDS values of the patients and controls.
Patient group (n=24) Control group
Time 0 Time 1 Time 2 (n=18)
GLP-1 0.1713±0.025** 0.1088±0.013*** 0.1079±0.0065x 0.1089±0.007
(ng/ml) (0.06-0.40) (0.03-0.35) (0.06-0.19) (0.06-0.16)
GLP-2 232±34† 60±4.69 ‡ 49.5±9.45x 44.03±3.57
(pg/100 µl) (64-536) (40-136) (32.6-68.5) (28-68)
BMI (kg/m2) 14.92±0.48* 16.31±0.46 18.2±0.57
(9.89-19.48) (11.6-21.04) (14.92-21.5)
BMI SDS –1.8±0.8* –1.05± 0.8 –1.02 ± 0.6
Time 0=Before treatment Time 1= When ketonemia resolved Time 2= When weight gain started
*p<0.05: time 0 vs control
**p<0.05: time 0 vs control
***p<0.05: time 0 vs time 1
†p< 0.01: time 0 vs control
‡p<0.05 and p<0.01: time 0 vs time 1 and time 1 vs control, respectively
Xp<0.05: time 2 vs time 02 (at 96 hours of treatment) when weight
gain started, and values were comparable to
those of the control subjects (Table 1,
Figures 1 and 2). 
In the patient group, there were no sig-
nificant correlations between age, body
weight, BMI SDS, HbA1c, insulin dose and
plasma GLP-1 and -2 levels except for a sig-
nificant negative correlation between the
GLP-2 levels and arterial pH values (r=
–0.26, p<0.05).
DISCUSSION
There are few studies about circulating
GLP-1 and GLP-2 levels in patients with
T1DM in the literature. Most of the studies
were performed in type 2 diabetic patients
(T2DM) and were based on GLP-1 response
to nutrient intake.(19, 20, 21, 22, 23, 24)
Some of these studies revealed that GLP-1
response to nutrient intake was reduced in
patients with T2DM as compared to healthy
controls,(21, 25) whereas in other studies it
was found to be increased or not
altered.(26, 27)In T1DM, preliminary studies
have suggested that endogenous secretion
of GLP-1 may be defective.(28) Other stud-
ies conducted among type 1 diabetics under
good metabolic control and on intensive
insulin regimen, fasting and postprandial
GLP-1 concentrations were found to be
near-normal or low, compared to healthy
subjects, and the decreased levels were
attributed to the existence of possible nega-
tive feed-back effect of insulin administrat-
ed exogenously.(22, 23, 24, 25)
Decreased blood glucose levels and also
reduction of glucose excursion after meals
were observed in recent-onset type 1 diabet-
ic patients treated with intravenous or subcu-
taneus GLP-1 with concurrent administration
of multiple dose insulin therapy. These
effects of GLP-1 were attributed to inhibition
of gastric emptying, enhancement of insulin
secretion, and also decreased glucagon secre-
tion.(9, 20, 22, 29, 30)Some studies, howev-
er, have reported negative results.(5, 31)
In the current study, we found elevation
of plasma GLP-1 and GLP-2 levels before the
start of DKA therapy. After starting treat-
ment, GLP-1 and GLP-2 levels started to
decrease in the first 8 hours during which
none of the patients consumed any food.
This result implies that food intake has no
direct effect on the changes of GLP-1 and
GLP-2 secretion in DKA. Thus, exogenous
insulin infusion seems to have led to the
decrease of plasma GLP-1 and GLP-2 levels
Figure 1: GLP-1 levels; before starting treatment (I) (time 0),
when ketonemia resolved (II) (time 1) and when weight gain
started (III) (time 2) in children with DKA and in control
subjects.
Figure 2: GLP-2 levels; before starting treatment (I) (time 0),
when ketonemia resolved (II) (time 1) and when weight gain
started (III) (time 2) in children with DKA and in control
subjects. 
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in our patients. Furthermore, we did not
detect any differences between plasma GLP-
1, and GLP-2 levels of the patients and con-
trols when weight gain started. Taken
together, our results suggest that insulin has
an inhibitory effect on GLP-1 and-2 secretion
and the glucose lowering actions of GLP-1
are regulated by insulin as reported before.
Although proteins and fatty acids were
found to stimulate or potentiate GLP-1
release in a number of studies,(32, 33, 34)
the underlying mechanisms have not yet
been clarified. Since the low-insulin catabol-
ic process is prominent in DKA, it may be
postulated that hyperglycemia and increased
plasma free fatty acid (FFA) levels may cause
GLP-1 release by stimulating the intestinal-L
cells. Furthermore, decreased renal blood
flux due to excessive fluid loss may be relat-
ed to the elevation of plasma GLP-1 and
GLP-2 levels in DKA.
A number of animal studies have
described elevated levels of both plasma
and tissue GLP-1 and GLP-2 in STZ-induced
diabetic rats without insulin therapy.(35, 36,
37, 38) The elevated GLP-2 concentrations
seen in STZ diabetes were prevented by
treatment with exogenous insulin, and it has
also been shown in animal studies that
insulin suppressed the increase of plasma
levels of GLPs as well as intestinal
growth.(18) In our study, the high plasma
GLP-2 in DKA can be ascribed to several fac-
tors, including insulin deficiency, increased
stress hormones, accumulation of ketone
bodies and dehydration. 
It has been shown that plasma GLP-2
levels are elevated in the setting of intestin-
al injury models in animals and in
humans.(39, 40) Acute abdominal pain, a
common feature of DKA may develop due
to mesenteric ischemia or to the irritative
effect of ketone bodies and improves with
resolution of the ketonemia after administra-
tion of fluids and insulin. Although mesen-
teric ischemia is uncommon in children,
there are a few reports of pediatric patients
with DKA who had mesenteric ischemia.(41,
42) In our study, none of the patients had
abdominal complaints and none were diag-
nosed as mesenteric ischemia. However,
non-occlusive bowel ischemia may occur as
a result of severe mesenteric vasospasm
which is a physiological response to hypov-
olemia and ineffective intestinal perfusion.
In DKA, severe dehydration and decreased
tissue perfusion associated with severe aci-
dosis are not uncommon, so that the
increased GLP-2 levels in DKA may be due
to severe dehydration and acidosis which
can lead to tissue hypoxia. The significant
negative correlation between the GLP-2 lev-
els and arterial pH values before treatment
established in the present study supports
this possibility. 
In conclusion, in our study, the increased
levels of GLP-1 and GLP-2 seem to be relat-
ed to insulin deficiency in DKA. Mesenteric
vasospasm which develops as a conse-
quence of hypovolemia and severe acidosis
may have contributed to the changes
observed in the plasma GLP-2 levels in DKA.
It is of interest that GLP-1 and GLP-2 levels
decreased following insulin infusion, indi-
cating the existence of a negative feed-back
effect between these hormones.
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